

# Patient-related factors influencing caregiver burden in Parkinson's disease patients: comparison of effects before and after deep brain stimulation.

Van Hienen, M.M.; Kuiper, R.; Middelkoop, H.A.M.; Van Hilten, J.J.; Contarino, M.F.; Geraedts, V.J.

#### Citation

Van Hienen, M. M., Kuiper, R., Middelkoop, H. A. M., Van Hilten, J. J., Contarino, M. F., & Geraedts, V. J. (2022). Patient-related factors influencing caregiver burden in Parkinson's disease patients: comparison of effects before and after deep brain stimulation. *Journal Of Parkinson's Disease*, *12*(4), 1285-1293. doi:10.3233/JPD-213093

Version:	Publisher's Version
License:	Creative Commons CC BY-NC 4.0 license
Downloaded from:	https://hdl.handle.net/1887/3512890

Note: To cite this publication please use the final published version (if applicable).

### **Research Report**

## Patient-Related Factors Influencing Caregiver Burden in Parkinson's Disease Patients: Comparison of Effects Before and After Deep Brain Stimulation

Marle M. Van Hienen<sup>a</sup>, Roy Kuiper<sup>a</sup>, Huub A.M. Middelkoop<sup>a,c</sup>, Jacobus J. Van Hilten<sup>a</sup>,

Maria Fiorella Contarino<sup>a,b</sup> and Victor J. Geraedts<sup>a,d,\*</sup>

<sup>a</sup>Department of Neurology, LUMC, Leiden, the Netherlands

<sup>b</sup>Department of Neurology, Haga Teaching Hospital, Den Haag, the Netherlands

<sup>c</sup>Institute of Psychology, Health, Medical and Neuropsychology Unit, Leiden University, Leiden, the Netherlands <sup>d</sup>Department of Clinical Epidemiology, LUMC, Leiden, the Netherlands

Accepted 23 February 2022 Pre-press 10 March 2022

#### Abstract.

**Background:** Caregivers of Parkinson's disease (PD) patients provide important support during the pre- and postoperative phase of deep brain stimulation (DBS). High levels of caregiver burden have been reported after DBS. However, a comparison between preoperative and postoperative burden and associated factors has been insufficiently studied.

**Objective:** To investigate the influence of DBS on caregiver burden, and to identify the differential impact of patient-related factors on caregiver burden before and after DBS.

**Methods:** Consecutive patients referred for DBS eligibility screening or during one-year follow-up assessments were included. Caregiver burden was measured with the short Zarit Burden Interview (ZBI-12). Inverse Probability Weighting (IPW) was used to compare caregiver burden between preoperative and postoperative assessments.

**Results:** We included 47 patients (24 screening, 23 follow-up) (median age 65 years, 29.4% female sex). DBS did not impact caregiver burden (screening: median ZBI-12 9.5 (IQR 3.25, 16.75); follow-up median ZBI-12 6 (IQR 4, 14); IPW-coefficient 0.57 (95% CI –2.75, 3.89)). Worse caregiver burden during DBS screening was associated with worse patient-related scores on depressive symptoms, anxiety, QoL, and impulsiveness. Worse scores on depressive symptoms, anxiety, apathy, postural-instability-gait-disorder, and QoL were associated with worse caregiver burden at one-year follow-up.

**Conclusion:** DBS appears not associated with changes in caregiver burden. Various symptoms are valued differently between screening and follow-up assessments in terms of caregiver burden. Early recognition of caregivers "at risk" may improve guidance of patient-caregiver dyads throughout the DBS process.

Keywords: Parkinson's disease, caregiver burden, deep brain stimulation, quality of life, epidemiology

\*Correspondence to: Victor J. Geraedts, MD, PhD, Department of Neurology, Albinusdreef 2, 2333ZA, Leiden, the Netherlands. E-mail: v.j.geraedts@lumc.nl.

#### INTRODUCTION

Parkinson's disease (PD) is characterized by both motor and non-motor symptoms, resulting in a significant reduction of quality of life (QoL) [1]. Caregivers

ISSN 1877-7171 © 2022 – The authors. Published by IOS Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC 4.0).

of PD patients are crucial contributors to maintaining patients' QoL despite disease progression, and concomitantly reduce both morbidity and mortality rates [2]. Given the variety and complexity of PD symptoms, a caregiver role may be highly demanding and cause a high burden for themselves. This may have a negative influence on their mental and general health [3], and social life [2–4], which in turn negatively influences the effectiveness and tolerability of caregiving [5].

PD patients with motor complications refractory to oral therapy may be eligible for deep brain stimulation (DBS) [6], which relieves motor complications and significantly improves QoL [7]. However, several PD motor and non-motor symptoms are stimulation-resistant and generally worsen as the disease advances [8]. Notably, non-motor symptoms may exert a larger negative influence on caregivers compared to motor symptoms [5]. The perioperative DBS setting imposes additional stress and raises an additional need of a well-functioning social support system [9, 10]. Early recognition of potentially problematic situations, and knowledge of modifiable factors influencing caregiver burden after DBS, may provide targets for supporting a well-functioning patient-caregiver dyad. In spite of the positive outcomes in PD patients, up to 50% of the caregivers rated their wellbeing as decreased after DBS in an earlier study [11].

Unfortunately, in previous observational studies the independent association between DBS and caregiver burden was not evaluated [5]. Therefore, the aim of this study was to investigate whether caregiver burden differs before DBS and one year after DBS, and determine which patient-related factors may influence caregiver burden both before and after DBS.

#### METHODS

#### Study participants

Consecutive patients referred to the Haga Teaching Hospital/Leiden University Medical Center (Haga/LUMC centre) for either screening for DBS eligibility, or consecutive patients seen during one year follow-up assessments, were prospectively included in this study. Subjects were therefore analyzed only once, no pre-post analysis was possible, and were divided in two separate groups. Patient selection began June 2019 and ended November 2020. All patients gave written informed consent. As this study used only data collected during routine clinical care, a formal ethical evaluation was waived by the local medical ethics committee.

#### Outcome measures

Motor function was assessed with the Movement Disorder Society Unified Parkinson's Disease Rating Scale part III (MDS UPDRS-III) and part IV (MDS UPDRS-IV) [12]. MDS-UPDRS III scores were assessed during the screening in the Med-ON and Med-OFF conditions, and in the Med-OFF/Stim-ON, Med-OFF/Stim-OFF, and Med-ON/Stim-ON conditions during follow-up assessments. The Med-OFF condition was achieved after an overnight withdrawal from anti-PD medication; the Med-ON condition was achieved through a suprathreshold dosage of 120% of the early morning Levodopa Equivalent Dose (LED) [13].

Anxiety symptoms were measured with the Parkinson Anxiety Scale (PAS) [14], severity of apathy with the Apathy Scale (AS) [15], autonomic symptoms with the Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction (SCOPA-AUT) [16], cognitive impairment with the Montreal Cognitive Assessment (MoCA) [17], depression with the Beck Depression Inventory-II (BDI-II) [18], the presence of impulsive behavior with the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) [19], Postural Instability and Gait Disorder (PIGD) symptoms with the Freezing of Gait questionnaire (FOG) [20], and QoL with both the 39-item Parkinson's Disease Questionnaire (PDQ-39) [21], and the 5 dimension EuroQoL (EQ-5D) [22]. Sleep disturbances were assessed with the Scales for Outcomes in Parkinson's Disease - Sleep (SCOPA-Sleep) [23], including Night-time Sleep Problems (NSP) and Excessive Daytime Sleepiness (EDS).

The abbreviated version of the Zarit Burden Interview (ZBI-12) was used to quantify caregiver burden. High caregiver burden was defined as a ZBI-12 score above 17 [24].

#### Statistical analysis

Demographics and clinical variables were compared between screening and one-year follow-up with independent Student's *T*-test, Mann-Whitney U test, and Chi-square test.

Two hypothetical causal frameworks surround caregiver burden related to DBS surgery: 1) Patientrelated covariates, such as neuropsychiatric symptoms or motor functioning, impact both DBS eligibility and caregiver burden after DBS and are therefore best considered confounding factors requiring additional correction, and 2) DBS has an effect on these covariates, which renders them mediators instead of confounders (i.e., the effect of DBS on caregiver burden is mediated through these variables, rather than a distorting effect). In this hypothetical framework, a correction of these mediators could lead to an underestimation of the actual effect of DBS on caregiver burden [25]. Directed Acyclic Graphs (DAGs) were used to reflect both scenarios (see Supplementary Figure 1A and B) [25]. Propensity scores based on the appropriate confounder-structures (different for each of the DAGs) were calculated and used to emulate randomization using Inverse Probability Weighting (IPW) [26, 27]. In the first situation, the propensity score was composed of the following confounders: patients' age, disease duration, motor symptoms, neuropsychiatric and cognitive symptoms, and PIGD. In the second situation, the propensity score was composed only of patients' age, and disease duration. This method allows comparability between groups in the absence of randomization.

An univariate linear regression analysis including demographic and clinical covariates was performed to determine the influence of patient-related factors on ZBI-12 scores. All assumptions for linear regression were checked prior to analysis. To evaluate whether the effect of the patient-related covariates differed between caregivers prior to surgery and during the one-year follow-up, univariate linear regression analyses were performed in three different strata: 1) Screening, 2) Follow-up, and 3) Combined. To model the combined effect of those covariates with the highest single impact (i.e., highest univariate  $\mathbf{R}^2$ ) on caregiver burden, a multivariable regression model was built. The total number of covariates in the multivariable regression model was based on the one covariate per ten patients rule [28].

The statistical analyses were performed with R Foundation for Statistical Computing version 4.0.3., and IBM Statistical Package for the Social Sciences 25 Software (SPSS).

#### RESULTS

#### Population characteristics

Between June 2019 and November 2020, 55 patients received either DBS screening or follow-up assessment. Six patients did not have a caregiver, and two patients returned incomplete questionnaires

(and were thus excluded). Forty-seven patients were ultimately included, of whom 24 were referred for DBS screening, and 23 patients had their followup assessment. Median patient age was 65 years, median caregiver age was 62 years. Forty-two caregivers were partners, two children, one parent, and two were sibling. The median ZBI-12 was 7, no statistical difference was found between screening and one-year follow-up. Nine caregivers in total experienced caregiver overload (ZBI-12  $\geq$  17) [24]. Further demographic variables are shown in Table 1. Patients referred for DBS eligibility screening had significantly better MDS-UPDRS III OFF scores than patients during the follow-up assessments (Med-OFF/Stim-OFF), but significantly worse scores in terms of motor fluctuations, autonomic symptoms, depression, impulsiveness, QoL, and NSP.

#### Impact of DBS on caregiver burden

Multivariable linear regression modelling of the first hypothetical scenario, i.e., with additional correction for PD symptoms, yielded a non-significant adjusted regression coefficient of 1.63 (95% CI–3.46, 6.73). Multivariable linear regression modelling of the second hypothetical scenario, i.e., only corrected for patients' age and disease duration, yielded a non-significant adjusted regression coefficient of -0.59 (95% CI–5.30, 4.13). The IPW regression coefficient was non-significant, i.e., 0.57 (95% CI–2.75, 3.89). All three results indicate no significant causal effect of DBS on caregiver burden.

#### Determinants of caregiver burden

Depression, anxiety, and patients' QoL were significantly associated with caregiver burden in all strata (screening, follow-up, and combined). Apathy and PIGD were found to be significant one year after DBS and in the combined stratum. Sleep disturbances were only significant when analyzing both screening- and follow-up patients simultaneously, and attentional impulsiveness was only significant in the screening stratum (see Table 2). Worse symptom severity was associated with higher caregiver burden.

The four following covariates were used in the multivariable regression model encompassing both screening and follow-up patients: patients' QoL (measured with the PDQ-39), depression, apathy, and PIGD. Only higher apathy scores were significantly associated with more caregiver burden in a multivariable model (see Table 3). A scatterplot

Screening $(N=24)$ Follow-up $(N=23)$ pAge caregiver <sup>a</sup> $61.5 (52.25, 69.75)$ $63 (61, 69)$ $0.33$ Sex caregiver, female <sup>b</sup> $70.8\% (17)$ $73.9\% (17)$ $0.8$ Relationship caregiver <sup>b</sup> $0.11$ $0.11$ Partner $91.7\% (22)$ $87\% (20)$ Child $8.3\% (2)$ $0\% (0)$ Parent $0\% (0)$ $4.3\% (1)$ Brother/Sister $0\% (0)$ $8.7\% (2)$ ZBI-12 <sup>a</sup> $9.50 (3.25, 16.75)$ $6 (4, 14)$ $0.70$ Caregiver overload <sup>b++</sup> $25\% (6)$ $13\% (3)$ $0.29$ Age patient <sup>a</sup> $64 (53.5, 68)$ $66 (57, 68)$ $0.66$ Disease duration <sup>a</sup> $6.05 (5.25, 8.625)$ $7.7 (6.7, 11)$ $0.09$ MDS-UPDRS III <sup>c</sup> $0N^*$ $18.33 (7.93)$ $21.29 (12.39)$ $0.34$ <i>OFF**</i> $39.88 (8.49)$ $49.41 (15.38)$ $0.00$ Mdd OFF / stim ON- $32.52 (12.30)$ -MDS-UPDRS IV <sup>c</sup> $10.05 (3.15)$ $4.91 (4.93)$ $> 0.02$ MDS-UPDRS IV <sup>c</sup> $10.05 (3.15)$ $4.91 (4.93)$ $> 0.02$ MDS-UPDRS IV <sup>c</sup> $12.33 (7.53)$ $7.87 (8.01)$ $0.002$ MDS-UPDRS IV <sup>c</sup> $12.5 (20.55)$ $7 (4, 12)$ $0.002$ MDS-UPRS IV <sup>c</sup> $12.05 (2.5, 28)$ $26 (25, 28)$ $0.92$ MDS-UPRS IV <sup>c</sup> $10.05 (3.15)$ $4.91 (4.93)$ $> 0.02$ MDS-UPRS IV <sup>c</sup> $10.05 (3.15)$ $4.91 (4.93)$ $> 0.02$ MDS-UPRS IV <sup>c</sup> $10.05 (3.15)$ $4.91 (4.93)$ $> 0.02$ MDS-UPRS IV <sup>c</sup> <t< th=""><th><i>p</i> .321 .813 .158 .709 .298 .631 .609</th></t<>	<i>p</i> .321 .813 .158 .709 .298 .631 .609
Age caregiver <sup>a</sup> $61.5 (52.25, 69.75)$ $63 (61, 69)$ $0.33$ Sex caregiver, female <sup>b</sup> $70.8\% (17)$ $73.9\% (17)$ $0.8$ Relationship caregiver <sup>b</sup> $0.11$ Partner $91.7\% (22)$ $87\% (20)$ Child $8.3\% (2)$ $0\% (0)$ Parent $0\% (0)$ $4.3\% (1)$ Brother/Sister $0\% (0)$ $8.7\% (2)$ ZBI-12 <sup>a</sup> $9.50 (3.25, 16.75)$ $6 (4, 14)$ $0.70$ Caregiver overload <sup>b++</sup> $25\% (6)$ $13\% (3)$ $0.22$ Age patient <sup>a</sup> $64 (53.5, 68)$ $66 (57, 68)$ $0.66$ Sex patient <sup>b</sup> female $37.5\% (9)$ $30.4\% (7)$ $0.60$ Disease duration <sup>a</sup> $6.05 (5.25, 8.625)$ $7.7 (6.7, 11)$ $0.09$ MDS-UPDRS III <sup>c</sup> $0N^*$ $18.33 (7.93)$ $21.29 (12.39)$ $0.34$ OFF** $39.88 (8.49)$ $49.41 (15.38)$ $0.00$ MDS-UPDRS IV <sup>c</sup> $10.05 (3.15)$ $4.91 (4.93)$ $> 0.00$ MDS-UPDRS IV <sup>c</sup> $10.05 (3.15)$ $4.91 (4.93)$ $> 0.00$ Ag <sup>a</sup> $11 (9, 13)$ $11.50 (9, 14.5)$ $0.44$ SCOPA-AUT <sup>c</sup> $18.58 (9.28)$ $13.13 (6.25)$ $0.00$ MoCA <sup>a</sup> $26 (25, 28)$ $26 (25, 28)$ $0.99$ BDI-II <sup>a</sup> $15.5 (10.5, 20.75)$ $7 (4, 12)$ $0.00$ QUIP-RS <sup>a</sup> $11.50 (2.25, 17.75)$ $1 (0, 12)$ $0.00$ FOG <sup>c</sup> $5.91 (5.49)$ $5.14 (4.65)$ $0.61$	.321 .813 .158 .709 .298 .631 .609
Sex caregiver, female $70.8\% (17)$ $73.9\% (17)$ $0.8$ Relationship caregiver $01.1\%$ Partner $91.7\% (22)$ $87\% (20)$ Child $8.3\% (2)$ $0\% (0)$ Parent $0\% (0)$ $4.3\% (1)$ Brother/Sister $0\% (0)$ $8.7\% (2)$ ZBI-12 <sup>a</sup> $9.50 (3.25, 16.75)$ $6 (4, 14)$ $0.7\% (2)$ Zge patient <sup>a</sup> $64 (53.5, 68)$ $66 (57, 68)$ $0.66$ Sex patient <sup>b,</sup> female $37.5\% (9)$ $30.4\% (7)$ $0.66$ Disease duration <sup>a</sup> $6.05 (5.25, 8.625)$ $7.7 (6.7, 11)$ $0.09$ MDS-UPDRS III <sup>c</sup> $0N^*$ $18.33 (7.93)$ $21.29 (12.39)$ $0.34$ $OFF^{**}$ $39.88 (8.49)$ $49.41 (15.38)$ $0.01$ MDS-UPDRS IV <sup>c</sup> $10.05 (3.15)$ $4.91 (4.93)$ $> 0.02$ $As^a$ $11 (9, 13)$ $11.50 (9, 14.5)$ $0.44$ SCOPA-AUT <sup>c</sup> $18.58 (9.28)$ $13.13 (6.25)$ $0.07$ MoCA <sup>a</sup> $26 (25, 28)$ $26 (25, 28)$ $0.99$ BDI-II <sup>a</sup> $15.5 (10.5, 20.75)$ $7 (4, 12)$ $0.00$ QUIP-RS <sup>a</sup> $11.50 (2.25, 17.75)$ $1 (0, 12)$ $0.07$ FOG <sup>c</sup> $5.91 (5.49)$ $5.14 (4.65)$ $0.66$	.813 .158 .709 .298 .631 .609
Relationship caregiver0.11Partner91.7% (22) $87\%$ (20)Child $8.3\%$ (2)0% (0)Parent0% (0) $4.3\%$ (1)Brother/Sister0% (0) $8.7\%$ (2)ZBI-12 <sup>a</sup> 9.50 (3.25, 16.75)6 (4, 14)0.70Caregiver overload $b^+$ 25% (6)13% (3)0.29Age patient <sup>a</sup> 64 (53.5, 68)66 (57, 68)0.66Sex patient <sup>b</sup> , female37.5% (9) $30.4\%$ (7)0.66Disease duration <sup>a</sup> 6.05 (5.25, 8.625)7.7 (6.7, 11)0.09MDS-UPDRS III <sup>c</sup> 00%-32.52 (12.30)-ON*18.33 (7.93)21.29 (12.39)0.34OFF**39.88 (8.49)49.41 (15.38)0.00MDS-UPDRS IV <sup>c</sup> 10.05 (3.15)4.91 (4.93)> 0.02Aga11 (9, 13)11.50 (9, 14.5)0.44SCOPA-AUT <sup>c</sup> 18.58 (9.28)13.13 (6.25)0.00MoCA <sup>a</sup> 26 (25, 28)26 (25, 28)0.99BDI-II <sup>a</sup> 15.5 (10.5, 20.75)7 (4, 12)0.00QUIP-RS <sup>a</sup> 11.50 (2.25, 17.75)1 (0, 12)0.00FOG <sup>c</sup> 5.91 (5.49)5.14 (4.65)0.66QoL patient5.14 (4.65)0.66	.158 .709 .298 .631 .609
Partner91.7% (22) $87\%$ (20)Child $8.3\%$ (2) $0\%$ (0)Parent $0\%$ (0) $4.3\%$ (1)Brother/Sister $0\%$ (0) $8.7\%$ (2)ZBI-12 <sup>a</sup> $9.50$ (3.25, 16.75) $6$ (4, 14) $0.7\%$ Caregiver overload <sup>b++</sup> $25\%$ (6) $13\%$ (3) $0.29$ Age patient <sup>a</sup> $64$ (53.5, 68) $66$ (57, 68) $0.65$ Sex patient <sup>b,</sup> female $37.5\%$ (9) $30.4\%$ (7) $0.66$ Disease duration <sup>a</sup> $6.05$ (5.25, 8.625) $7.7$ (6.7, 11) $0.09$ MDS-UPDRS III <sup>c</sup> $ 32.52$ (12.39) $0.34$ $OFF^{**}$ $39.88$ (8.49) $49.41$ (15.38) $0.00$ Med OFF / stim ON $ 32.52$ (12.30) $-$ MDS-UPDRS IV <sup>c</sup> $10.05$ (3.15) $4.91$ (4.93) $> 0.02$ $As^a$ $11$ (9, 13) $11.50$ (9, 14.5) $0.44$ SCOPA-AUT <sup>c</sup> $18.58$ (9.28) $13.13$ (6.25) $0.00$ MoCA <sup>a</sup> $26$ (25, 28) $26$ (25, 28) $0.99$ BDI-II <sup>a</sup> $15.5$ (10.5, 20.75) $7$ (4, 12) $0.00$ QUIP-RS <sup>a</sup> $11.50$ (2.25, 17.75) $1$ (0, 12) $0.07$ FOG <sup>c</sup> $5.91$ (5.49) $5.14$ (4.65) $0.66$	.709 .298 .631 .609
Child $8.3\%$ (2) $0\%$ (0)Parent $0\%$ (0) $4.3\%$ (1)Brother/Sister $0\%$ (0) $8.7\%$ (2)ZBI-12 <sup>a</sup> $9.50$ (3.25, 16.75) $6$ (4, 14) $0.70$ Caregiver overload <sup>b++</sup> $25\%$ (6) $13\%$ (3) $0.29$ Age patient <sup>a</sup> $64$ (53.5, 68) $66$ (57, 68) $0.62$ Sex patient <sup>b,</sup> female $37.5\%$ (9) $30.4\%$ (7) $0.66$ Disease duration <sup>a</sup> $6.05$ (5.25, 8.625) $7.7$ (6.7, 11) $0.09$ MDS-UPDRS III <sup>c</sup> $00\%$ $ 32.52$ (12.39) $0.34$ $OFF^{**}$ $39.88$ (8.49) $49.41$ (15.38) $0.00$ Med OFF / stim ON $ 32.52$ (12.30) $-$ MDS-UPDRS IV <sup>c</sup> $10.05$ (3.15) $4.91$ (4.93) $> 0.02$ $As^a$ $11$ (9, 13) $11.50$ (9, 14.5) $0.44$ SCOPA-AUT <sup>c</sup> $18.58$ (9.28) $13.13$ (6.25) $0.00$ MocA <sup>a</sup> $26$ (25, 28) $26$ (25, 28) $0.99$ BDI-II <sup>a</sup> $15.5$ (10.5, 20.75) $7$ (4, 12) $0.00$ QUIP-RS <sup>a</sup> $11.50$ (2.25, 17.75) $1$ (0, 12) $0.07$ FOG <sup>c</sup> $5.91$ (5.49) $5.14$ (4.65) $0.66$ QoL patient $00$ $00$	.709 .298 .631 .609
Parent0% (0)4.3% (1)Brother/Sister0% (0)8.7% (2)ZBI-12a9.50 (3.25, 16.75)6 (4, 14)0.70Caregiver overload $^{b+}$ 25% (6)13% (3)0.29Age patienta64 (53.5, 68)66 (57, 68)0.60Sex patientb- female37.5% (9)30.4% (7)0.60Disease durationa6.05 (5.25, 8.625)7.7 (6.7, 11)0.09MDS-UPDRS IIIc0N*18.33 (7.93)21.29 (12.39)0.34OFF**39.88 (8.49)49.41 (15.38)0.00Med OFF / stim ON-32.52 (12.30)-MDS-UPDRS IVc10.05 (3.15)4.91 (4.93)>0.00MAS-UPDRS IVc10.05 (3.15)4.91 (4.93)>0.00MAS-UPDRS IVc10.55 (3.15)4.91 (4.93)>0.00MAS-UPDRS IVc10.55 (3.15)4.91 (4.93)>0.00PASc12.33 (7.53)7.87 (8.01)0.00ASa11 (9, 13)11.50 (9, 14.5)0.44SCOPA-AUTc18.58 (9.28)13.13 (6.25)0.00MoCAa26 (25, 28)26 (25, 28)0.99BDI-IIa15.5 (10.5, 20.75)7 (4, 12)0.00QUIP-RSa11.50 (2.25, 17.75)1 (0, 12)0.00FOGc5.91 (5.49)5.14 (4.65)0.61QoL patient5.91 (5.49)5.14 (4.65)0.61	.709 .298 .631 .609
Brother/Sister0% (0) $8.7\%$ (2)ZBI-12a9.50 (3.25, 16.75)6 (4, 14)0.70Caregiver overload <sup>b+</sup> 25% (6)13% (3)0.29Age patient <sup>a</sup> 64 (53.5, 68)66 (57, 68)0.60Sex patient <sup>b,</sup> female37.5% (9)30.4% (7)0.60Disease duration <sup>a</sup> 6.05 (5.25, 8.625)7.7 (6.7, 11)0.09MDS-UPDRS III <sup>c</sup> 0N*18.33 (7.93)21.29 (12.39)0.34OFF**39.88 (8.49)49.41 (15.38)0.00Med OFF / stim ON-32.52 (12.30)-MDS-UPDRS IV <sup>c</sup> 10.05 (3.15)4.91 (4.93)>0.00MAS <sup>a</sup> 11 (9, 13)11.50 (9, 14.5)0.44SCOPA-AUT <sup>c</sup> 18.58 (9.28)13.13 (6.25)0.00MoCA <sup>a</sup> 26 (25, 28)26 (25, 28)0.90BDI-II <sup>a</sup> 15.5 (10.5, 20.75)7 (4, 12)0.00QUIP-RS <sup>a</sup> 11.50 (2.25, 17.75)1 (0, 12)0.00FOG <sup>c</sup> 5.91 (5.49)5.14 (4.65)0.61QoL patient15.5 (10.5, 20.75)7 (4, 12)0.00	.709 .298 .631 .609
ZBI- $12^a$ 9.50 (3.25, 16.75)6 (4, 14)0.70Caregiver overload $b^+$ 25% (6)13% (3)0.29Age patient $a$ 64 (53.5, 68)66 (57, 68)0.60Sex patient $b^-$ female37.5% (9)30.4% (7)0.60Disease duration $a$ 6.05 (5.25, 8.625)7.7 (6.7, 11)0.09MDS-UPDRS IIIc00%999.44 (15.38)0.00OFF**39.88 (8.49)49.41 (15.38)0.00Md OFF / stim ON-32.52 (12.30)-MDS-UPDRS IVc10.05 (3.15)4.91 (4.93)>0.00MAS-UPDRS IVc10.05 (3.15)4.91 (4.93)>0.00MAS-UPDRS IVc10.50 (9.14.5)0.44SCOPA-AUTc18.58 (9.28)13.13 (6.25)0.00MOCA $a$ 26 (25, 28)26 (25, 28)0.99BDI-II $a$ 15.5 (10.5, 20.75)7 (4, 12)0.00QUIP-RS $a$ 11.50 (2.25, 17.75)1 (0, 12)0.00FOGc5.91 (5.49)5.14 (4.65)0.65QoL patient5.14 (4.65)0.65	.709 .298 .631 .609
Caregiver overload $b^+$ 25% (6)13% (3)0.29Age patienta64 (53.5, 68)66 (57, 68)0.60Sex patientb, female37.5% (9)30.4% (7)0.60Disease durationa6.05 (5.25, 8.625)7.7 (6.7, 11)0.09MDS-UPDRS IIIc $0N^*$ 18.33 (7.93)21.29 (12.39)0.34OFF**39.88 (8.49)49.41 (15.38)0.00Mde OFF / stim ON-32.52 (12.30)-MDS-UPDRS IVc10.05 (3.15)4.91 (4.93)>0.00PASc12.33 (7.53)7.87 (8.01)0.00ASa11 (9, 13)11.50 (9, 14.5)0.44SCOPA-AUTc18.58 (9.28)13.13 (6.25)0.00MoCAa26 (25, 28)26 (25, 28)0.90BDI-IIa15.5 (10.5, 20.75)7 (4, 12)0.00QUIP-RSa11.50 (2.25, 17.75)1 (0, 12)0.00FOGc5.91 (5.49)5.14 (4.65)0.61QoL patient $0$ $0$ $0$	.298 .631 .609
Age patienta $64 (53.5, 68)$ $66 (57, 68)$ $0.66$ Sex patientb, female $37.5\% (9)$ $30.4\% (7)$ $0.66$ Disease durationa $6.05 (5.25, 8.625)$ $7.7 (6.7, 11)$ $0.09$ MDS-UPDRS IIIc $0N^*$ $18.33 (7.93)$ $21.29 (12.39)$ $0.34$ $OFF^{**}$ $39.88 (8.49)$ $49.41 (15.38)$ $0.00$ $Med OFF / stim ON$ $ 32.52 (12.30)$ $-$ MDS-UPDRS IVc $10.05 (3.15)$ $4.91 (4.93)$ $> 0.00$ PASc $12.33 (7.53)$ $7.87 (8.01)$ $0.00$ ASa $11 (9, 13)$ $11.50 (9, 14.5)$ $0.44$ SCOPA-AUTc $18.58 (9.28)$ $13.13 (6.25)$ $0.00$ MoCAa $26 (25, 28)$ $26 (25, 28)$ $0.90$ BDI-IIa $15.5 (10.5, 20.75)$ $7 (4, 12)$ $0.00$ QUIP-RSa $11.50 (2.25, 17.75)$ $1 (0, 12)$ $0.00$ POGc $5.91 (5.49)$ $5.14 (4.65)$ $0.61$	.631 .609
Sex patient <sup>b.</sup> female $37.5\%$ (9) $30.4\%$ (7) $0.60$ Disease duration <sup>a</sup> $6.05$ (5.25, 8.625) $7.7$ (6.7, 11) $0.09$ MDS-UPDRS III <sup>c</sup> $0N^*$ $18.33$ (7.93) $21.29$ (12.39) $0.34$ $OFF^{**}$ $39.88$ (8.49) $49.41$ (15.38) $0.00$ $Med OFF / stim ON$ $ 32.52$ (12.30) $-$ MDS-UPDRS IV <sup>c</sup> $10.05$ (3.15) $4.91$ (4.93) $>0.00$ PAS <sup>c</sup> $12.33$ (7.53) $7.87$ (8.01) $0.00$ AS <sup>a</sup> $11$ (9, 13) $11.50$ (9, 14.5) $0.44$ SCOPA-AUT <sup>c</sup> $18.58$ (9.28) $13.13$ (6.25) $0.00$ MoCA <sup>a</sup> $26$ (25, 28) $26$ (25, 28) $0.90$ BDI-II <sup>a</sup> $15.5$ (10.5, 20.75) $7$ (4, 12) $0.00$ QUIP-RS <sup>a</sup> $11.50$ (2.25, 17.75) $1$ (0, 12) $0.05$ FOG <sup>c</sup> $5.91$ (5.49) $5.14$ (4.65) $0.65$ QoL patient $5.91$ (5.49) $5.14$ (4.65) $0.65$	.609
Disease duration a $6.05 (5.25, 8.625)$ $7.7 (6.7, 11)$ $0.09$ MDS-UPDRS III° $0N^*$ $18.33 (7.93)$ $21.29 (12.39)$ $0.34$ $OFF^{**}$ $39.88 (8.49)$ $49.41 (15.38)$ $0.00$ $Med OFF / stim ON$ $ 32.52 (12.30)$ $-$ MDS-UPDRS IV° $10.05 (3.15)$ $4.91 (4.93)$ $> 0.00$ PAS° $12.33 (7.53)$ $7.87 (8.01)$ $0.00$ ASa $11 (9, 13)$ $11.50 (9, 14.5)$ $0.44$ SCOPA-AUT° $18.58 (9.28)$ $13.13 (6.25)$ $0.00$ MoCAa $26 (25, 28)$ $26 (25, 28)$ $0.90$ BDI-IIa $15.5 (10.5, 20.75)$ $7 (4, 12)$ $0.00$ QUIP-RSa $11.50 (2.25, 17.75)$ $1 (0, 12)$ $0.00$ FOG° $5.91 (5.49)$ $5.14 (4.65)$ $0.61$ QoL patient $0.01$ $0.02$	005
MDS-UPDRS III° $21.29 (12.39)$ $0.34$ $OFF^{**}$ $39.88 (8.49)$ $49.41 (15.38)$ $0.01$ $Med OFF / stim ON$ - $32.52 (12.30)$ -MDS-UPDRS IV° $10.05 (3.15)$ $4.91 (4.93)$ $>0.02$ PAS° $12.33 (7.53)$ $7.87 (8.01)$ $0.02$ ASa11 (9, 13) $11.50 (9, 14.5)$ $0.44$ SCOPA-AUT° $18.58 (9.28)$ $13.13 (6.25)$ $0.02$ MoCAa $26 (25, 28)$ $26 (25, 28)$ $0.99$ BDI-IIa $15.5 (10.5, 20.75)$ $7 (4, 12)$ $0.00$ QUIP-RSa $11.50 (2.25, 17.75)$ $1 (0, 12)$ $0.02$ FOG° $5.91 (5.49)$ $5.14 (4.65)$ $0.65$ QoL patient $5.14 (4.65)$ $0.65$	.095
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	
$OFF^{**}$ 39.88 (8.49)         49.41 (15.38)         0.0           Med OFF / stim ON         -         32.52 (12.30)         -           MDS-UPDRS IV <sup>c</sup> 10.05 (3.15)         4.91 (4.93)         > 0.0           PAS <sup>c</sup> 12.33 (7.53)         7.87 (8.01)         0.00           AS <sup>a</sup> 11 (9, 13)         11.50 (9, 14.5)         0.44           SCOPA-AUT <sup>c</sup> 18.58 (9.28)         13.13 (6.25)         0.00           MoCA <sup>a</sup> 26 (25, 28)         26 (25, 28)         0.90           BDI-II <sup>a</sup> 15.5 (10.5, 20.75)         7 (4, 12)         0.00           QUIP-RS <sup>a</sup> 11.50 (2.25, 17.75)         1 (0, 12)         0.00           QoL patient         5.91 (5.49)         5.14 (4.65)         0.64	.340
Med OFF / stim ON- $32.52 (12.30)$ -MDS-UPDRS IV° $10.05 (3.15)$ $4.91 (4.93)$ > $0.0$ PAS° $12.33 (7.53)$ $7.87 (8.01)$ $0.02$ ASa $11 (9, 13)$ $11.50 (9, 14.5)$ $0.44$ SCOPA-AUT° $18.58 (9.28)$ $13.13 (6.25)$ $0.02$ MoCAa $26 (25, 28)$ $26 (25, 28)$ $0.90$ BDI-IIa $15.5 (10.5, 20.75)$ $7 (4, 12)$ $0.00$ QUIP-RSa $11.50 (2.25, 17.75)$ $1 (0, 12)$ $0.02$ FOG° $5.91 (5.49)$ $5.14 (4.65)$ $0.62$ QoL patient $0.22 (25, 28)$ $0.22 (25, 28)$ $0.22 (25, 28)$	.012
MDS-UPDRS IV° $10.05 (3.15)$ $4.91 (4.93)$ > $0.0$ PAS° $12.33 (7.53)$ $7.87 (8.01)$ $0.02$ ASa $11 (9, 13)$ $11.50 (9, 14.5)$ $0.44$ SCOPA-AUT° $18.58 (9.28)$ $13.13 (6.25)$ $0.02$ MoCAa $26 (25, 28)$ $26 (25, 28)$ $0.90$ BDI-IIa $15.5 (10.5, 20.75)$ $7 (4, 12)$ $0.00$ QUIP-RSa $11.50 (2.25, 17.75)$ $1 (0, 12)$ $0.02$ FOG° $5.91 (5.49)$ $5.14 (4.65)$ $0.62$ QoL patient $0.91 (2.25, 17.75)$ $0.91 (2.25, 17.75)$	_
PASc $12.33$ (7.53) $7.87$ (8.01) $0.02$ ASa $11$ (9, 13) $11.50$ (9, 14.5) $0.44$ SCOPA-AUTc $18.58$ (9.28) $13.13$ (6.25) $0.02$ MoCAa $26$ (25, 28) $26$ (25, 28) $0.90$ BDI-IIa $15.5$ (10.5, 20.75) $7$ (4, 12) $0.00$ QUIP-RSa $11.50$ (2.25, 17.75) $1$ (0, 12) $0.02$ FOGc $5.91$ (5.49) $5.14$ (4.65) $0.65$ QoL patient $0.25$ $0.25$ $0.25$	).001
ASa11 (9, 13)11.50 (9, 14.5) $0.44$ SCOPA-AUTc18.58 (9.28)13.13 (6.25) $0.02$ MoCAa26 (25, 28)26 (25, 28) $0.90$ BDI-IIa15.5 (10.5, 20.75)7 (4, 12) $0.00$ QUIP-RSa11.50 (2.25, 17.75)1 (0, 12) $0.02$ FOGc5.91 (5.49)5.14 (4.65) $0.62$ QoL patient $0.02$ $0.02$	.055
$\begin{array}{ccccccc} SCOPA-AUT^c & 18.58 \ (9.28) & 13.13 \ (6.25) & 0.02 \\ MoCA^a & 26 \ (25, 28) & 26 \ (25, 28) & 0.90 \\ BDI-II^a & 15.5 \ (10.5, 20.75) & 7 \ (4, 12) & 0.00 \\ QUIP-RS^a & 11.50 \ (2.25, 17.75) & 1 \ (0, 12) & 0.02 \\ FOG^c & 5.91 \ (5.49) & 5.14 \ (4.65) & 0.60 \\ QoL patient & & & & \\ \end{array}$	.444
MoCAa $26 (25, 28)$ $26 (25, 28)$ $0.90$ BDI-IIa $15.5 (10.5, 20.75)$ $7 (4, 12)$ $0.00$ QUIP-RSa $11.50 (2.25, 17.75)$ $1 (0, 12)$ $0.00$ FOGc $5.91 (5.49)$ $5.14 (4.65)$ $0.60$ QoL patient $0.01 (2.25, 17.75)$ $0.01 (2.25, 17.75)$	.023
BDI-IIa $15.5 (10.5, 20.75)$ $7 (4, 12)$ $0.00$ QUIP-RSa $11.50 (2.25, 17.75)$ $1 (0, 12)$ $0.00$ FOG <sup>c</sup> $5.91 (5.49)$ $5.14 (4.65)$ $0.60$ QoL patient $0.00$ $0.00$ $0.00$	.905
QUIP-RS <sup>a</sup> 11.50 (2.25, 17.75)         1 (0, 12)         0.05           FOG <sup>c</sup> 5.91 (5.49)         5.14 (4.65)         0.65           QoL patient         0.05         0.05         0.05	.001
FOG <sup>c</sup> 5.91 (5.49)         5.14 (4.65)         0.6           QoL patient         0.6	.032
QoL patient	.612
$PDQ-39^{\circ}$ 47.79 (22.32) 31.61 (23.36) 0.02	.019
$EQ-5D^{c}$ 10.08 (2.78) 8.57 (2.39) 0.03	.051
SCOPA Sleep	
$NSP^{c}$ 7.00 (3.74) 4.30 (3.52) 0.02	.015
<i>EDS</i> <sup>c</sup> 4.96 (3.62) 4.39 (2.94) 0.55	.559
Overall sleep quality <sup>b</sup> 0.14	.144
Very well $0\% (0) 26.1\% (6)$	
Well 8.7% (2) 17.4% (4)	
<i>Rather well</i> 21.7% (5) 17.4% (4)	
<i>Not well but not badly</i> 26.1% (6) 17.4% (4)	
Rather badly 26.1% (6) 17.4% (4)	
Badly 13% (3) 4.3% (1)	
Very badly 4.3% (1) 0% (0)	

Table 1 Population characteristics

<sup>a</sup>Mann-Whitney U test, Median (25% IQR, 75% IQR). <sup>b</sup>Chi-square test, % (N). <sup>c</sup>Unpaired *T*-test, Mean ( $\pm$ SD). \*The ON situation was defined as 1.2 times the patients' early morning dose at time of screening. At time of follow-up, the ON situation was defined as both 1.2 times the patients' early morning dose and activate DBS device. \*\*The OFF situation was defined as at least 12 hours absence of anti-parkinsonian medication at time of screening. At time of follow-up, the OFF situation was defined as both 12 hours absence of anti-parkinsonian medication and DBS device was switched off. +Caregiver overload  $\geq$  17. <sup>++</sup>NSP  $\geq$  7. <sup>+++</sup>EDS  $\geq$  5. ZBI-12, 12-item Zarit Burden Interview; MDS-UPDRS, Movement Disorder Society Unified Parkinson's Disease Rating Scale; PAS, Parkinson Anxiety Scale; AS, Apathy Scale; SCOPA-AUT, Scales for Outcome in Parkinson's Disease – Autonomic Dysfunction; BDI-II, Beck Depression Inventory II; QUIP-RS, Questionnaire for Impulsive-Compulsive disorders in Parkinson's Disease – Rating Scale; FOG, Freezing of Gait questionnaire; MoCA, Montreal Cognitive Assessment; PDQ-39, 39-item Parkinson's Disease Questionnaire; EQ-5D, five dimension EuroQoL; SCOPA-Sleep, Scales for Outcome in Parkinson's Disease – Sleep; NSP, Nighttime Sleeping Problems; EDS, Excessive Daytime Sleeping.

of the unstandardized predicted values versus the observed values is shown in Supplementary Figure 2A. A second multivariable regression model incorporating anxiety scores instead of depression scores (i.e., due to the collinearity between depression and anxiety), showed relatively similar results (see Supplementary Table 1 and Supplementary Figure 2B).

	Screening		Follow-up		Combined	
	β	95% CI	β	95% CI	β	95% CI
Patients' age	-0.071	-0.382, 0.241	-0.107	-0.572, 0.358	-0.085	-0.334, 0.164
Disease duration	-0.143	-0.527, 0.241	0.078	-0.943, 1.098	-0.111	-0.452, 0.231
MDS-UPDRS III 'ON'*	0.246	-0.168, 0.660	0.229	-0.084, 0.542	0.229	-0.001, 0.459
MDS-UPDRS III 'OFF'**	0.298	-0.080, 0.675	0.093	-0.163, 0.349	0.113	-0.070, 0.297
MDS-UPDRS IV	-0.200	-1.440, 1.040	0.158	-0.632, 0.947	0.051	-0.480, 0.581
BDI-II	0.599	0.201, 0.997	0.985	0.521, 1.448	0.603	0.334, 0.873
PAS	0.475	0.076, 0.874	0.546	0.138, 0.955	0.482	0.220, 0.743
SCOPA-AUT	0.308	-0.031, 0.648	0.176	-0.431, 0.783	0.251	-0.027, 0.528
SCOPA-Sleep	0.584	-0.286, 1.453	0.950	-0.047, 1.947	0.684	0.097, 1.271
PDQ-39	0.208	0.087, 0.329	0.242	0.121, 0.363	0.203	0.125, 0.282
EQ-5D	1.256	0.169, 2.343	2.249	1.017, 3.482	1.561	0.802, 2.321
MoCA	-0.014	-1.756, 1.727	0.159	-1.270, 1.587	0.097	-0.941, 1.135
QUIP-RS	0.424	0.118, 0.729	0.013	-0.437, 0.464	0.223	-0.026, 0.472
AS	0.574	-0.425, 1.572	1.097	0.467, 1.727	0.920	0.417, 1.422
FOG	0.249	-0.391, 0.888	1.333	0.736, 1.929	0.689	0.242, 1.136

 Table 2

 Effect of (univariate) patient-related covariates on caregiver burden

\*The ON situation was defined as 1.2 times the patients' early morning dose at time of screening. At time of follow-up, the ON situation was defined as both 1.2 times the patients' early morning dose and activate DBS device. \*\*The OFF situation was defined as at least 12 hours absence of anti-parkinsonian medication at time of screening. At time of follow-up, the OFF situation was defined as both 12 hours absence of anti-parkinsonian medication and DBS device was switched off. MDS-UPDRS, Movement Disorder Society – Unified Parkinson's Disease Rating Scale; BDI-II, Beck Depression Inventory II; PAS, Parkinson Anxiety Scale; SCOPA-AUT, Scales for Outcome in Parkinson's Disease – Autonomic Dysfunction; SCOPA-Sleep, Scales for Outcome in Parkinson's Disease – Sleep; PDQ-39, 39-item Parkinson's Disease Questionnaire; EQ-5D, five dimension EuroQoL; MoCA, Montreal Cognitive Assessment; QUIP-RS, Questionnaire for Impulsive-Compulsive disorders in Parkinson's Disease – Rating Scale; AS, Apathy Scale; FOG, Freezing of Gait questionnaire.

 Table 3

 Multivariable regression analysis model

Questionnaire	β	р	95% CI	$\mathbb{R}^2$
PDQ-39	0.095	0.210	-0.056, 0.246	0.496
BDI-II	0.268	0.217	-0.166, 0.702	
AS	0.641	0.014	0.139, 1.144	
FOG	0.008	0.974	-0.468, 0.483	

Constant: B = -5.503; p = 0.069; 95% CI = -11.459 - 0.452. PDQ-39, 39-item Parkinson's Disease Questionnaire; BDI-II, Beck Depression Inventory II; AS, Apathy Scale; FOG, Freezing of Gait Questionnaire.

#### DISCUSSION

The complexity and variety of PD symptoms can make caring for a PD patient a challenging task [2]. In this study, we investigated the influence of DBS on caregiver burden and determined the differential impact of patient-related factors on caregiver burden before and after DBS.

Despite results from observational studies, a causal effect of DBS on caregiver burden has not been established. Randomized controlled trials (RCTs) focusing on caregiver burden are not feasible in the setting, and current observational studies carry inherent selection bias and information bias [4]. Although RCTs are widely considered to be the gold standard in determining causal structures, emulation of such trials may model underlying causal structures as well [27]. Our Emulated Target Trial observed no independent association between DBS and caregiver burden; scores for caregiver burden did not differ between patients before and after surgery even after adjustment for other relevant covariates. A previous observational study suggested that this may be due to an increase in caregiver demands after DBS surgery [29]. Moreover, both the current study, as well as previous studies, indicates that neuropsychiatric symptoms of PD such as depression, anxiety, and apathy may have a great influence on caregiver burden, even more so than motor symptoms [5]. Also it has been suggested that newly emerged or progressively worsening of neuropsychiatric symptoms may occur because of malfunctioning of the patient-caregiver dyad [30].

Covariates with a significant influence on worse caregiver burden in both the screening- and follow-up strata were worse depression scores, anxiety scores, and QoL. Additionally, more impulsiveness was significantly associated with worse caregiver burden in caregivers of DBS candidates, but not in caregivers of patients who already received DBS. After DBS-STN surgery, the patients' dopaminergic drug dose is decreased, which most likely reduces impulsiveness (as exemplified in the lower level of QUIP-RS scores in the follow-up population) [30]. We hypothesize that the reduced variability in impulsiveness scores resulted in the non-significant association of QUIP-RS and caregiver burden in the follow-up stratum. Similarly, worse apathy scores and PIGD scores were significantly associated in caregivers of patients one year after DBS, but not in caregivers of DBS candidates. We hypothesize that these symptoms stand out more after DBS due to the relief of motor fluctuations and perceived improvement of motor function in general [31], causing a relatively higher impact on caregivers than experienced prior to surgery despite similar objective symptom severity scores. Moreover, we hypothesize that the relief of motor symptoms could even lead to an unrealistic desire of caregivers to return to "normal", which was not possible due to a lack of motivation caused by a higher degree apathy. Previous literature has shown some discrepancy in apathy prevalence after DBS, with some studies reporting an increased prevalence with other studies reporting no significant increase [32]. A different study suggested a personal or familial diathesis for mood disturbances, including apathy, regardless of DBS [33]. Even if DBS does not aggravates apathy, the impact of apathy may be larger due to both its under-recognition and its resilience to treatment [32]. Further investigation is required to explore the differential impact of apathy with regard to DBS candidates and patients post-surgery.

The similar symptom severity scores indicate that disease progression or an effect of medicationalterations likely did not contribute to the disparity between the baseline and follow-up groups. Similarly, we observed a relatively larger influence of depression and general QoL in the follow-up stratum than in the screening stratum, although depressive symptoms were considerably lower in the follow-up stratum. Another possibility is that these symptoms persist despite an (unrealistic) desire for improvement [34], causing disappointment of the caregiver and concomitant higher caregiver burden.

Our findings on the influence of depression, anxiety and impulsiveness and lack of influence of motor symptoms on caregiver burden are in line with previous studies [30, 35, 36]. In contrast, previous studies did not find a significant influence of patient QoL on caregiver burden [36]. This may be explained by the fact that whilst baseline scores of the PDQ-39 are relatively similar (i.e., 48.2 vs. 47.8), whereas we observed markedly better QoL scores at follow-up (i.e., 41.6 vs. 31.6). We hypothesize that the better QoL scores in our study may have had a beneficial effect on caregiver burden compared to studies with relatively worse QoL. The significant association between apathy and PIGD and caregiver burden, as well as the non-significant association of sleep disturbances, has not been previously described in previous studies and may have additional utility during patient- and caregiver education during the DBS screening [5]. Strikingly, patients' cognitive function was not associated with caregiver burden in our cohort, despite being associated with caregiver burden in the general population [37]. Previous literature found that the ZBI-12 scale correlated poorly with cognitive dysfunction [24]. Strikingly, the only significant covariate in our multivariable model was apathy, highlighting the importance of neuropsychiatric symptoms on caregiver burden during the DBS process. Finally, we speculate that other instruments to assess caregiver burden may find a significant association with cognition after all. Our model explained close to 50% of the total variance, indicating that there are several other determinants influencing caregiver burden.

Limitations of this study include a lack of caregiver-related covariates due to the data collection during routine clinical care. Although sex and age of the caregiver were known, these could not be included in the analyses due to collinearity. Second, our cross-sectional study design made it impossible to perform an in-patient analysis. As a result of the COVID-19 pandemic, most follow-up appointments were considered non-essential care and postponed until further notice. Only patients with suboptimal disease control would receive a follow-up appointment, whereas outpatient-appointments of patients with adequate disease control were considered nonessential, which would have resulted in a considerable selection bias. The lack of a control-group could be construed as a limitation but was circumvented by using IPW analyses. Although our sample size is still relatively small, it clearly exceeds previous studies on this topic (i.e., between 12 and 30 patient-caregiver dyads) [5]. Moreover, our study assessed the contribution of patient-related covariates that are typical components of most DBS screening procedures, thus increasing the utility of our findings for clinical practice.

A major limitation is the lack of a control group and/or a longitudinal design including longitudinal within-patient assessments. Ideally, a RCT would validate our findings using a randomized and blinded pre-post assessment of caregiver burden, using either sham-stimulation or actual DBS. A limitation of this design, regardless of ethical considerations to withhold patients beneficial therapy, is that this disregards non-stimulation-induced effects such as stun-effects or lesion-effects due to lead insertion. Another option would include longitudinal assessments of caregiver burden in DBS-candidates either approved or rejected for the DBS screening. However, this would introduce a major selection bias since patients reject for DBS are inherently different from patients who are found to be suitable DBS candidates, as they may be rejected for a variety of reasons including cognitive deficits or suboptimal oral treatment [34].

Future research should investigate to what degree caregiver-related covariates influence postoperative caregiver burden (i.e., presurgical expectations of caregivers), and whether interventions can be implemented to further relieve caregiver burden after DBS. A previous study described that 27% of caregivers would appreciate professional help after DBS surgery [38]. An intervention-study for caregivers, targeting DBS-related changes, consisted of cognitive-behavioral therapy at weekly intervals and resulted in a substantial reduction of caregiver burden, which was maintained until three months after completing the intervention [39]. It remains to be determined whether these interventions are suitable for all caregivers (even with low scores on caregiver burden instruments), and whether the effects of these interventions are maintained during long-term follow-up.

Further investigation is required to study other potential variables such as sociodemographic variables (i.e., Western vs. non-Western society), surgical timing, mood disturbances other than apathy, fatigue, and sleep disturbances, and their relation to possible dissatisfaction with surgery [40]. In particular, stimulation-induced dysarthria and/or fatigue has to our knowledge not been studied in relation to caregiver burden, however its impact needs to be studied further as these may negatively influence communication with caregivers [41, 42]. This may potentially make them unwilling to participate in life-events, which could further impair the patientcaregiver dyad.

A previous systematic review identified a favorable patient profile for caregiver wellbeing assessed during the DBS screening, which included younger patient age, younger age-at-onset, lower disease duration, lower LED, lower validations on psychiatric rating scales, and higher relationship quality [5]. Additions of this study to this favorable profile for better caregiver outcome after surgery include lower ratings on the QoL scales, lower apathy scores and lower PIGD ratings. Early recognition of this favorable patient profile may benefit both patients and caregivers during the DBS screening and may improve patient- and caregiver education on postoperative expectations [34]. Caregivers "at risk" for high levels of caregiver burden after surgery could be early identified with these influencing factors, both before and after DBS, which makes early interventions and counselling feasible to counteract any negative effects of a non-functional social support system [30].

In conclusion, DBS is not independently associated with caregiver burden, but several patient-related factors were identified to significantly impact caregivers and may be targets for modelling caregiver burden during both the screening phase and follow-up period after DBS, with a particular emphasis on neuropsychiatric covariates. Attention to caregivers "at risk" for high levels of caregiver burden is crucial for maintaining a functional social support system supporting the patient surrounding the time of surgery, which is beneficial for patients, caregivers, and the patient-caregiver dyad.

#### ACKNOWLEDGMENTS

The authors would like to thank EL Fu PhD for his aid during the statistical analyses, and GEL Hendriks for her help during data collection.

#### **CONFLICT OF INTEREST**

MM van Hienen reports nothing to disclose.

MF Contarino: Advisory board: Medtronic (fees to institution); Consultancies: Medtronic, BostonScientific, Inbrain: independent consultant for research and educational issues (fees to institution); Speaking fees: ECMT. Research support: Medtronic: unrestricted educational grant (to institution). Abbvie: grant support (to institution). Global Kinetics Corporation: research support (in-kind).

R Kuiper reports nothing to disclose.

HAM Middelkoop reports nothing to disclose.

JJ van Hilten received grants from Alkemade-Keuls Foundation; Stichting Parkinson Fonds; The Netherlands Organisation for Health Research and Development; The Netherlands Organisation for Scientific Research; Hersenstichting; AbbVie; Hoffmann-La-Roche; Lundbeck; and Centre for Human Drug Research outside the submitted work.

VJ Geraedts reports nothing to disclose.

#### SUPPLEMENTARY MATERIAL

The supplementary material is available in the electronic version of this article: https://dx.doi.org/ 10.3233/JPD-213093.

#### REFERENCES

- [1] van Uem JM, Marinus J, Canning C, van Lummel R, Dodel R, Liepelt-Scarfone I, Berg D, Morris ME, Maetzler W (2016) Health-related quality of life in patients with Parkinson's disease–A systematic review based on the ICF model. *Neurosci Biobehav Rev* 61, 26-34.
- [2] Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M (2006) Caregiver-burden in Parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. *Parkinsonism Relat Disord* 12, 35-41.
- [3] Smith ER, Perrin PB, Tyler CM, Lageman SK, Villaseñor T (2019) Parkinson's symptoms and caregiver burden and mental health: A cross-cultural mediational model. *Behav Neurol* 2019, 1396572.
- [4] Tolosa E, Ebersbach G, Ferreira JJ, Rascol O, Antonini A, Foltynie T, Gibson R, Magalhaes D, Rocha JF, Lees A (2021) The Parkinson's Real-World Impact Assessment (PRISM) study: A European survey of the burden of Parkinson's disease in patients and their carers. *J Parkinsons Dis* 11, 1309-1323.
- [5] van Hienen MM, Contarino MF, Middelkoop HAM, van Hilten JJ, Geraedts VJ (2020) Effect of deep brain stimulation on caregivers of patients with Parkinson's disease: A systematic review. *Parkinsonism Relat Disord* 81, 20-27.
- [6] Beitz JM (2014) Parkinson's disease: A review. Front Biosci (Schol Ed) 6, 65-74.
- [7] Lewis CJ, Maier F, Eggers C, Pelzer EA, Maarouf M, Moro E, Zurowski M, Kuhn J, Woopen C, Timmermann L (2014) Parkinson's disease patients with subthalamic stimulation and carers judge quality of life differently. *Parkinsonism Relat Disord* 20, 514-519.
- [8] Moro E, Lang AE (2006) Criteria for deep-brain stimulation in Parkinson's disease: Review and analysis. *Expert Rev Neurother* 6, 1695-1705.
- [9] Haahr A, Kirkevold M, Hall EO, Ostergaard K (2013) 'Being in it together': Living with a partner receiving deep brain stimulation for advanced Parkinson's diseasea hermeneutic phenomenological study. J Adv Nurs 69, 338-347.
- [10] Haahr A, Ostergaard K, Kirkevold M (2018) "It is hard work, but it is worth it": Patients and spouses' experiences of a nursing intervention to promote adjustment to deep brain stimulation for Parkinson's disease-a feasibility study. ANS Adv Nurs Sci 41, 174-187.
- [11] Lewis CJ, Maier F, Horstkotter N, Eggers C, Visser-Vandewalle V, Moro E, Zurowski M, Kuhn J, Woopen C, Timmermann L (2015) The impact of subthalamic deep brain stimulation on caregivers of Parkinson's disease patients: An exploratory study. *J Neurol* 262, 337-345.
- [12] Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale

(MDS-UPDRS): Scale presentation and clinimetric testing results. *Mov Disord* 23, 2129-2170.

- [13] Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. *Mov Disord* 25, 2649-2653.
- [14] Leentjens AF, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin P (2014) The Parkinson Anxiety Scale (PAS): Development and validation of a new anxiety scale. *Mov Disord* 29, 1035-1043.
- [15] Lopez FV, Eglit GML, Schiehser DM, Pirogovsky-Turk E, Litvan I, Lessig S, Filoteo JV (2019) Factor analysis of the Apathy Scale in Parkinson's disease. *Mov Disord Clin Pract* 6, 379-386.
- [16] Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ (2004) Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA-AUT. *Mov Disord* 19, 1306-1312.
- [17] Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 53, 695-699.
- [18] Smarr KL, Keefer AL (2011) Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9). Arthritis Care Res (Hoboken) 63(Suppl 11), S454-466.
- [19] Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A (2012) Questionnaire for impulsive-compulsive disorders in Parkinson's Disease-Rating Scale. *Mov Disord* 27, 242-247.
- [20] Giladi N, Shabtai H, Simon ES, Biran S, Tal J, Korczyn AD (2000) Construction of freezing of gait questionnaire for patients with Parkinsonism. *Parkinsonism Relat Disord* 6, 165-170.
- [21] Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N (1997) The Parkinson's Disease Questionnaire (PDQ-39): Development and validation of a Parkinson's disease summary index score. *Age Ageing* 26, 353-357.
- [22] (1990) EuroQol-a new facility for the measurement of health-related quality of life. *Health Policy* 16, 199-208.
- [23] Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM (2003) Assessment of sleep and sleepiness in Parkinson disease. *Sleep* 26, 1049-1054.
- [24] Stagg B, Larner A (2015) Zarit Burden Interview: Pragmatic study in a dedicated cognitive function clinic. *Prog Neurol Psychiatry* 19, 23-27.
- [25] Greenland S, Pearl J, Robins JM (1999) Causal diagrams for epidemiologic research. *Epidemiology* 10, 37-48.
- [26] Fu Y, Gao W, Zhu M, Chen X, Lin Z, Wang S (2009) Computer-assisted automatic localization of the human pedunculopontine nucleus in T1-weighted MR images: A preliminary study. *Int J Med Robot* 5, 309-318.
- [27] Hernán MA, Robins JM (2016) Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol 183, 758-764.
- [28] Austin PC, Steyerberg EW (2017) Events per variable (EPV) and the relative performance of different strategies for estimating the out-of-sample validity of logistic regression models. *Stat Methods Med Res* 26, 796-808.
- [29] Jackowiak E, Maher AC, Persad C, Kotagal V, Wyant K, Heston A, Patil PG, Chou KL (2020) Caregiver burden worsens in the second year after subthalamic nucleus deep brain

stimulation for Parkinson's disease. *Parkinsonism Relat Disord* **78**, 4-8.

- [30] Mosley PE, Breakspear M, Coyne T, Silburn P, Smith D (2018) Caregiver burden and caregiver appraisal of psychiatric symptoms are not modulated by subthalamic deep brain stimulation for Parkinson's disease. *NPJ Parkinsons Dis* 4, 12.
- [31] Geraedts VJ, van Hilten JJ, Marinus J, Mosch A, Naarding KJ, Hoffmann CFE, van der Gaag NA, Contarino MF (2019) Stimulation challenge test after STN DBS improves satisfaction in Parkinson's disease patients. *Parkinsonism Relat Disord* 69, 30-33.
- [32] Rossi M, Bruno V, Arena J, Cammarota Á, Merello M (2018) Challenges in PD patient management after dbs: A pragmatic review. *Mov Disord Clin Pract* 5, 246-254.
- [33] Berney A, Vingerhoets F, Perrin A, Guex P, Villemure JG, Burkhard PR, Benkelfat C, Ghika J (2002) Effect on mood of subthalamic DBS for Parkinson's disease: A consecutive series of 24 patients. *Neurology* 59, 1427-1429.
- [34] Geraedts VJ, Kuijf ML, van Hilten JJ, Marinus J, Oosterloo M, Contarino MF (2019) Selecting candidates for deep brain stimulation in Parkinson's disease: The role of patients' expectations. *Parkinsonism Relat Disord* 66, 207-211.
- [35] Soileau MJ, Persad C, Taylor J, Patil PG, Chou KL (2014) Caregiver burden in patients with Parkinson disease undergoing deep brain stimulation: An exploratory analysis. J Parkinsons Dis 4, 517-521.

- [36] Soulas T, Sultan S, Gurruchaga JM, Palfi S, Fenelon G (2012) Changes in quality of life, burden and mood among spouses of Parkinson's disease patients receiving neurostimulation. *Parkinsonism Relat Disord* 18, 602-605.
- [37] Connors MH, Seeher K, Teixeira-Pinto A, Woodward M, Ames D, Brodaty H (2019) Mild cognitive impairment and caregiver burden: A 3-year-longitudinal study. *Am J Geriatr Psychiatry* 27, 1206-1215.
- [38] Baumann-Vogel H, Bodenmann G, Schmid J, Waldvogel D, Ineichen C, Baumann CR (2020) Partners' view after subthalamic deep brain stimulation: Better relationships despite patients being less active. *Clin Park Relat Disord* 3, 100052.
- [39] Mosley PE, Robinson K, Dissanayaka NN, Coyne T, Silburn P, Marsh R, Pye D (2020) A pilot trial of cognitive behavioral therapy for caregivers after deep brain stimulation for Parkinson's disease. J Geriatr Psychiatry Neurol 34, 454-465.
- [40] Jabre MG, Bejjani BP (2007) Neurosurgery in Parkinson disease: A distressed mind in a repaired body? *Neurology* 68, 1164; author reply 1164-1165.
- [41] Skodda S (2012) Effect of deep brain stimulation on speech performance in Parkinson's disease. *Parkinsons Dis* 2012, 850596.
- [42] Kluger BM, Parra V, Jacobson C, Garvan CW, Rodriguez RL, Fernandez HH, Fogel A, Skoblar BM, Bowers D, Okun MS (2012) The prevalence of fatigue following deep brain stimulation surgery in Parkinson's disease and association with quality of life. *Parkinsons Dis* 2012, 769506.